Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors ...

Regenerative medicine is the branch of medicine that develops methods to regrow, repair or replace damaged or diseased cells, organs or tissues. Regenerative medicine includes the generation and ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in ... our unique ability to repeatedly and consistently translate science into medicine has led to ...

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Personalized medicine is a therapeutic approach involving the use of an individual’s genetic and epigenetic information to tailor drug therapy or preventive care. We developed an endothelial ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

Distrust over the track record of domestically produced medicine runs deep in China. Such concerns spiraled into public uproar last month over the alleged questionable quality of Chinese generic ...

Sanofi’s Sarclisa has received approval in more than 50 nations and regions. Credit: LCV/Shutterstock. Sanofi’s Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that provide a clearer look at how the Teva-partnered prospect compares to Merck ...